Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 50

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 50
---
 As a result, purchasers of shares from the Selling
Shareholders could pay more or less per share than investors in our best efforts offering who will have purchased Units at a fixed price.
In addition, rapid market sales or sales in significant volumes of the shares by the Selling Shareholders may significantly dilute the
value of our common stock held by investors in our primary offering, resulting in depreciation of the value of shares purchased at a
fixed price per Unit paid by investors in the primary offering and/or significant volatility in the price of our shares.

<div align='center'>26</div>

Until such time as the shares of Common Stock are quoted on the OTCQX or the OTCQB marketplace of OTC Market or are listed on a national securities exchange, the concurrent offering by the Selling Stockholders in the resale offering may adversely affect the success of our Primary Offering.

We anticipate that the selling shareholders
resale offering will be concurrently conducted when our primary offering of units is still ongoing. The concurrent resale offering by
the Selling stockholders at a fixed per share price of $1.00 until such time as our Common Stock is quoted on the OTCQX or the OTCQB
marketplace or until the shares of our Common Stock are listed on a national securities exchange can adversely affect our ability to
raise capital in the primary offering as the fixed resale price of $1.00 per share can be deemed by prospective investors as more attractive
than the $3.20 price per unit in the primary offering, which can adversely affect the success of our primary offering. In the event that
for whatever reason our Common Stock is not upgraded to the OTCQB or OTCQX tier of OTC Marketplace, of which no assurance can be provided,
then we believe the concurrent offering by the Selling Stockholders may adversely affect the primary offering.

The sale of shares of our Common Stock by Selling Stockholders could cause the price of our Common Stock to fall and the issuance and sale of Common Stock upon exercise of warrants by Selling Stockholders will cause dilution. The issuance of our Common Stock by the Company in the Primary Offering and upon exercise of our outstanding warrants in this Offering will cause immediate and substantial dilution.

Sales of a substantial
number of shares of our Common Stock by Selling Stockholders in the public market, or the perception that these sales might occur, could
depress the market price of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities.
We are unable to predict the